TheraCyte Cell Encapsulation System IDE Slated For Second Quarter
This article was originally published in The Gray Sheet
Executive Summary
TheraCyte, Inc. plans to file an investigational device exemption with FDA during the second quarter for a Phase I study intended to evaluate the TheraCyte encapsulated cell technology implant system.
You may also be interested in...
Genzyme Spinning Off Surgical Division, Transferring NeuroCell In-House
Genzyme General plans to spin off its surgical products business into a separately traded company by the third quarter of 1999 in order to accelerate growth in both businesses, the Cambridge, Massachusetts-based firm announced March 4 in reporting 1998 year-end results.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.